Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.
We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy. Fourteen days after discontinuation of G-CSF therapy his monocyte counts returned to normal levels and a marrow aspirate showed a reduction in blast cells. He received further chemotherapy without G-CSF and without any recurrence of the raised leucocyte count but failed to achieve full remission. Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.
Ranaghan
L
L
Department of Haematology, Belfast City Hospital, UK.
Drake
M
M
Humphreys
M W
MW
Morris
T C
TC
D000368:Aged; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000150:complications* / Q000188:drug therapy*; D007955:Leukemoid Reaction / Q000209:etiology* / Q000473:pathology*; D007964:Leukocytosis / Q000139:chemically induced; D008297:Male; D009000:Monocytes / Q000473:pathology*
D016179:Granulocyte Colony-Stimulating Factor